Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Fox

Orthopaedic Surgery Hershey, PA Medical Doctor

NPI 1023051331 CMS profile 819292

30 Hope Dr, Ec-089, Hershey, PA 17033

Open in the dashboard

General payments

$35,422

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Fox of Hershey, PA is reported in the CMS Open Payments database as having received $35,422 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $784 10
2024 General $3,216 16
2023 General $1,099 22
2022 General $1,198 23
2021 General $8,727 21
2020 General $1,787 7
2019 General $18,612 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Fox
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Edward Fox were reported at $784. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Edward Fox Orthopaedic Surgery median Middle half National median
2019 $18,612 $644 $140–$2,844 $163
2020 $1,787 $312 $75–$1,860 $114
2021 $8,727 $520 $117–$2,495 $132
2022 $1,198 $598 $128–$2,731 $149
2023 $1,099 $461 $128–$2,264 $160
2024 $3,216 $497 $134–$2,475 $164
2025 $784 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $18,349 10 payments
  2. Genzyme Corporation $8,669 5 payments
  3. Deciphera Pharmaceuticals Inc. $2,680 6 payments
  4. Amgen Inc. $1,371 20 payments
  5. UCB, Inc. $937 11 payments
  6. Radius Health, Inc. $928 10 payments
  7. Alexion Pharmaceuticals, Inc. $880 8 payments
  8. Stryker Corporation $515 16 payments
  9. Daiichi Sankyo Inc. $256 3 payments
  10. Novartis Pharmaceuticals Corporation $246 20 payments
  11. Other $590 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,369 9 payments
  2. Food and Beverage $5,540 88 payments
  3. Travel and Lodging $4,136 7 payments
  4. Honoraria $1,755 1 payment
  5. Consulting Fee $550 1 payment
  6. Education $73 9 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $9,322 4 payments
  2. TECFIDERA $8,881 5 payments
  3. AUBAGIO $8,669 5 payments
  4. VIMSELTINIB $2,555 5 payments
  5. Prolia $501 12 payments
  6. STRENSIQ $323 3 payments
  7. EVENITY $319 3 payments
  8. Turalio $256 3 payments
  9. GAMMA $223 6 payments
  10. KESIMPTA $175 17 payments
  11. Other $1,662 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

664

Median for Orthopedic Surgery: 203

Drug cost

$793,845

Median for Orthopedic Surgery: $1,433

Branded share of claims

63.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tymlos Abaloparatide Brand 147 $389,800
Forteo Teriparatide Brand 64 $235,732
Teriparatide Generic 56 $151,632
Oxycontin Oxycodone Hcl Brand 11 $11,057
Ultra-Fine Mini Pen Needle Pen Needle, Diabetic Brand 77 $1,328
Oxycodone Hcl Generic 57 $1,048
Ultra-Fine Nano Pen Needle Pen Needle, Diabetic Brand 66 $1,030
Diclofenac Sodium Generic 28 $601
Celecoxib Generic 20 $445
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $304

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$36,339

Medicare's payments for the services billed

Medicare patients

323

Average age 74

Services billed

472

251 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Osteoporosis 75%
High blood pressure 66%
Arthritis 60%
Depression 26%
Cancer 25%
Diabetes 21%
Ischemic heart disease 19%
Chronic kidney disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STRENSIQ
  • Alexion Pharmaceuticals, Inc. $107
$107 — —
OGSIVEO
  • SpringWorks Therapeutics, Inc. $101
$101 — —
Turalio
  • Daiichi Sankyo Inc. $20
$20 — —
Tymlos
  • Radius Health, Inc. $17
$17 147 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record